PTC Therapeutics (NASDAQ:PTCT) Insider Sells $211,964.16 in Stock

Posted by Defense World Staff on Feb 23rd, 2026

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) insider Neil Gregory Almstead sold 3,056 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total transaction of $211,964.16. Following the transaction, the insider directly owned 112,140 shares of the company’s stock, valued at approximately $7,778,030.40. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Neil Gregory Almstead also recently made the following trade(s):

On Wednesday, February 18th, Neil Gregory Almstead sold 65 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.36, for a total transaction of $4,508.40.
On Thursday, January 8th, Neil Gregory Almstead sold 59 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.45, for a total transaction of $4,510.55.
On Thursday, January 8th, Neil Gregory Almstead sold 881 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.45, for a total transaction of $67,352.45.
On Wednesday, January 7th, Neil Gregory Almstead sold 52 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total transaction of $4,028.96.
On Wednesday, January 7th, Neil Gregory Almstead sold 1,026 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total transaction of $79,494.48.
On Tuesday, January 6th, Neil Gregory Almstead sold 54 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $4,155.30.
On Tuesday, January 6th, Neil Gregory Almstead sold 1,279 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $98,419.05.
On Monday, November 24th, Neil Gregory Almstead sold 35,572 shares of PTC Therapeutics stock. The shares were sold at an average price of $80.18, for a total value of $2,852,162.96.
On Tuesday, November 25th, Neil Gregory Almstead sold 71,928 shares of PTC Therapeutics stock. The shares were sold at an average price of $83.44, for a total transaction of $6,001,672.32.

PTC Therapeutics Stock Performance

NASDAQ:PTCT opened at $70.66 on Monday. The stock has a market capitalization of $5.85 billion, a PE ratio of 9.13 and a beta of 0.48. PTC Therapeutics, Inc. has a fifty-two week low of $35.95 and a fifty-two week high of $87.50. The company has a fifty day moving average of $74.91 and a two-hundred day moving average of $68.14.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. The company had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. During the same quarter last year, the business earned ($0.85) EPS. The firm’s revenue for the quarter was down 22.7% compared to the same quarter last year. Research analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PTCT shares. Royal Bank Of Canada lowered their price target on PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating on the stock in a research note on Friday. Barclays upgraded PTC Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $68.00 to $119.00 in a report on Tuesday, January 27th. Morgan Stanley reaffirmed an “overweight” rating and set a $90.00 target price on shares of PTC Therapeutics in a report on Thursday, January 8th. Jefferies Financial Group increased their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Finally, Wells Fargo & Company lowered their price target on shares of PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating on the stock in a research report on Friday. Ten equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $80.73.

Read Our Latest Research Report on PTCT

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. UMB Bank n.a. purchased a new stake in shares of PTC Therapeutics in the fourth quarter valued at about $26,000. Smartleaf Asset Management LLC raised its stake in PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 236 shares during the period. Optiver Holding B.V. boosted its holdings in PTC Therapeutics by 96.5% in the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 249 shares during the last quarter. Comerica Bank grew its stake in shares of PTC Therapeutics by 868.5% in the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 469 shares during the period. Finally, Salomon & Ludwin LLC acquired a new stake in shares of PTC Therapeutics during the 4th quarter worth approximately $41,000.

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.